Sharemaestro Newsreel

Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip

PAVmed Inc. (PAVM) reported a narrower GAAP net loss of $5.5 million, or $0.87 per share, in Q2 2026, down from $12.3 million a year earlier, driven by lower non-cash charges. Despite progress in its Lucid Diagnostics, Veris, PortIO, and Octeris programs, the stock …

Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop

Werewolf Therapeutics Company Profile & Introduction

Bausch Health Stock Gains Momentum as Stronger Earnings, Raised Outlook and Debt Progress Lift Investor Optimism

Wedbush Reaffirms "Outperform" Rating for Fate Therapeutics (NASDAQ:FATE)

Wedbush has reaffirmed an "Outperform" rating for Fate Therapeutics (NASDAQ:FATE), setting a target price of $7.00, which suggests a significant upside of approximately 178% from its current share price. The biopharmaceutical company recently surpassed quarterly expectations, reporting a smaller-than-anticipated loss of $0.25 per share …

Fresenius Medical Care stock steadies around $23 as investors weigh recent buybacks and guidance

Fresenius Medical Care stock is trading steadily around $23 in mid-August 2026, influenced by recent share buybacks and a modest year-to-date decline. The company's capital allocation strategy now includes renewed willingness for buybacks, alongside guidance for continued mid-single-digit revenue growth and improved operating income …

Autolus Therapeutics (AUTL): Armistice Capital discloses 15M-share, 5.64% ADS stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 15,000,000 American Depositary Shares (ADSs) in Autolus Therapeutics plc (AUTL), representing 5.64% of the outstanding ADSs. The shares are held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as the …

Armistice Capital (CALC) discloses 3.41M-share, 9.99% holding in CalciMedica

Armistice Capital, LLC and Steven Boyd have reported a significant holding in CalciMedica, Inc., disclosing beneficial ownership of 3,411,361 shares, which represents 9.99% of the company's common stock. The shares are directly held by Armistice Capital Master Fund Ltd., with Armistice Capital serving as …

Forte Biosciences earnings on deck as $2.2 billion argenx deal nears

Forte Biosciences is set to report its second-quarter earnings, which are expected to be largely a formality as the company awaits the completion of its $2.2 billion acquisition by argenx. Analysts anticipate a loss of $1.01 per share on zero revenue for Forte. The …

ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx

SueWallSt has initiated an investigation into potential securities law violations by Ardelyx (NASDAQ: ARDX) following a significant drop in its stock price. The company lowered its 2026 IBSRELA revenue guidance by up to $80 million and withdrew its long-term XPHOZAH revenue target, citing payer …

UBS Adjusts Price Target on Acadia Healthcare to $1.50 From $4.50, Keeps Neutral Rating

UBS has adjusted its price target for Acadia Healthcare (referred to as Accendra Health in the article) to $1.50, down from $4.50, while maintaining a Neutral rating on the stock. This adjustment follows similar downgrades and price target reductions from other firms like Citigroup …

Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in BioXcel Therapeutics, Inc. (BTAI), amounting to 1,621,716 shares. These shares are held through Armistice Capital Master Fund Ltd., with Armistice Capital exercising shared voting and dispositive power as the investment …

Artelo Biosciences (ARTL) major holder reports 0% ownership in new 13G/A

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G/A for Artelo Biosciences (ARTL), reporting that they no longer beneficially own any common stock in the company. As of June 30, 2026, their ownership stake is 0 shares, representing 0.0% of the …

Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)

Are Investors Undervaluing Tenet Healthcare (THC) Right Now?

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in …

Trinity Biotech secures $7m from Perceptive Advisors By Investing.com

Trinity Biotech (NASDAQ:TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, comprising $2.5 million in new debt and $4.5 million in capitalized interest. This funding will support the company's CGM+ continuous glucose monitoring platform, Trinovium subsidiary, and diagnostics …

Form 8K Lifeward Ltd. For: 14 August By Investing.com

This article reports on the filing of Form 8K by Lifeward Ltd. on August 14th. It appears to be a standard financial news brief from Investing.com, providing basic information about the filing and its publication details.

Quantum Biopharma Ltd. (CN:QNTM) Shares Decline as Biotech Uncertainty, Funding Risks and Clinical Development Challenges Pressure Investor Sentiment

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Why Did Oscar Health (OSCR) Fall After Record Profit and a Guidance Hike?

Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net …

Trinity Biotech Secures Additional $7.0 Million Investment from Perceptive Advisors and Regains Compliance with Nasdaq Minimum Bid Price Requirement

Trinity Biotech (NASDAQ: TRIB) has secured an additional $7.0 million investment from Perceptive Advisors, its largest financial investor, and has regained compliance with Nasdaq's minimum bid price requirement. The investment, consisting of new debt funding and capitalized interest, aims to bolster liquidity for strategic …

Trinity Biotech Regains Nasdaq Compliance After 10 Days at $1 or More

Canton Strategic Holdings (CNTN) posts $66.6M loss amid big Canton Coin bet

Embecta (EMBC) Q3 2026 Earnings Call Transcript

Rapid Micro Biosystems (RPID) Q2 2026 Earnings Call Transcript

DOCS|Doximity Inc|Price:26.375|Chg%:-0.215

JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock

Stifel cuts Nkarta stock price target on updated model By Investing.com

Stifel has lowered its price target for Nkarta Inc. (NASDAQ:NKTX) to $10 from $11, while maintaining a Buy rating, following the company's Q2 2026 earnings and an updated financial model. The adjustment comes after discussions with Nkarta's management regarding patient enrollment progress in its …

Tenet Healthcare Corporation (THC) Hits Fresh High: Is There Still Room to Run?

Shares of Tenet Healthcare (THC) have been strong performers lately, with the stock up 34.1% over the past month. The stock hit a new 52-week high of $270.57 in the previous session. Tenet has gained 34.4% since the start of the year compared to …

AMN Healthcare Services (NYSE:AMN) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

BioMarin Pharmaceutical (BMRN) is outperforming the Medical sector and its specific industry year-to-date, with a 15.3% return compared to the sector's 3%. The company holds a Zacks Rank #2 (Buy) due to improving analyst sentiment. Cardinal Health (CAH) is another medical stock showing strong …

Oppenheimer Adjusts PT on Abeona Therapeutics to $21 From $22, Maintains Outperform Rating

Oppenheimer has revised its price target for Abeona Therapeutics (ABEO) to $21 from $22, while reiterating an Outperform rating on the stock. This adjustment comes after Abeona Therapeutics' shares fell following a Q2 earnings miss. The article also provides a company profile, recent news, …

Skye Bioscience (NASDAQ: SKYE) exits obesity trial, pursues Redx merger and $100M+ funding

Skye Bioscience is discontinuing its nimacimab obesity program and pursuing a merger with Redx Pharma to form Fibrx Therapeutics, Inc. This strategic shift addresses significant financial strains, as evidenced by a $23.3 million net loss and a substantial doubt about its ability to continue …

Skye Bioscience, Inc. 2026: Revenue $178.2K, EPS ($0.27) — 10-Q Summary

Skye Bioscience, Inc. reported its 2026 quarterly results, showing revenue of $178.2K and a net loss of ($10.79M), leading to a diluted loss per share of ($0.27), which is an improvement over the prior year. The company also announced the termination of its CBeyond …

Clover Health Is Proving Its Profit Model (NASDAQ:CLOV)

Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

Wedbush reiterated its "outperform" rating on Zenas BioPharma (NASDAQ:ZBIO) with a $45 price target, indicating a potential 54.11% upside. Despite this positive analyst sentiment, the company reported a significant miss on its quarterly earnings and revenue estimates. Other analysts have also adjusted their ratings, …